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Abstract 
Introduction: Numerous perinatal 
complications of diabetes in pregnancy have been 
recognised. Maternal post-partum complications 
can be equally devastating.  
Method: In this study, a cohort of known type 
1 and type 2 pregnant diabetics and newly 
diagnosed Gestational Diabetes Mellitus (GDM) 
patients were analysed. Data collected was analysed 
in terms of method of diagnosis, gestational age at 
diagnosis for GDM, relevant medical or obstetric 
history, subsequent management and follow up. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Results: Out of 79 viable pregnancies, 69.6% 
of patients were diagnosed with GDM, 13.9% with 
type 2 DM and 16.5% with type 1 DM. Mean 
gestational age for the GDM cohort was 37.9 (±1.6) 
weeks, 35.5 (±3.7) weeks in Type 2 and 37.1 (±0.7) 
weeks in the Type 1 cohort (p=0.010). 20.3% of all 
cohort and specifically 23.6% of GDM pregnancies 
had a fetus which was large for gestational age. 
30% of GDM patients, 25.5% of Type 2 DM 
patients and 84.6% of Type 1 DM patients, had 
their blood glucose controlled by an insulin infusion 
pump peri-partum. Mean HbA1C in the third 
trimester was 6.0%, 6.3% and 7.1% in GDM, Type 
2 and Type 1 diabetics respectively (p=0.004). A 
negative correlation was seen between HbA1C 
levels in third trimester and delivery gestational age 
(p<0.001).  
Conclusion: Our findings emphasize the need 
for close follow up of these patients. Implementing 
a structured and holistic multidisciplinary team may 
have an impact on outcome, focusing on maternal 
education, in particular in GDM patients and their 
risk of developing type 2 DM in the future. 
 
Introduction 
Diabetes mellitus (DM) is the most common 
medical condition complicating a pregnancy, 
affecting 16% of all life births1. Diabetes is the 
epidemic of the 21st century, with recorded increase 
in the incidence globally. Possibly, one may 
attribute this to an increased tendency for a 
sedentary lifestyle and a shift towards a western 
diet. The unmodifiable genetic predisposition is a 
major determinant which is quite relevant to the 
Maltese population. The prevalence of gestational 
diabetes in Malta was 15.5% in 2010 based on 
WHO criteria,2 rising up to 16.5% when using the 
International Association of Diabetes and 
Pregnancy Study Groups (IADPSG) criteria.3-4 A 
rise in obesity  and delayed childbearing age have 
led to an increase incidence of gestational diabetes 
mellitus (GDM) and earlier onset of type 2 diabetes 
mellitus . The potential devastating effects of 
diabetes can affect both the mother and fetus with 
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the management and outcomes differing according 
to the aetiology of the condition. 
This retrospective study conducted at Mater 
Dei Hospital in Malta, has analysed how pregnant 
mothers who had diabetes during pregnancy (GDM, 
type 1 & type 2 DM) are diagnosed and managed, 
further focusing on follow-up and subsequent 
maternal and fetal outcome. 
 
Methods and Materials 
A retrospective study consisting of a cohort of 
type 1, type 2 and newly diagnosed GDM patients, 
over a 5-year period.  These patients consisted of all 
consecutive patients who presented to a single firm 
with any of the mentioned conditions in the study 
period.  Our study comprised of 79 pregnancies, of 
which 69.6% were diagnosed with GDM, 16.5% 
were Type 1 DM patients and 13.9% Type 2 DM 
patients. The IADPSG criteria (Figure 1) was used 
for diagnosing GDM, based on an oral glucose 
tolerance test (OGTT) according to risk factors at 
booking and a fasting blood glucose level above 5.1 
mmol/l. Risk factors for GDM include a high body 
mass index (BMI), strong first-degree family 
history of type 2 DM, severe polycystic ovarian 
syndrome (PCOS), previous unexplained stillbirth 
or macrosomia and macrosomia or polyhydramnios 
during the index pregnancy. However, two GDM 
cases were diagnosed during the third trimester of 
pregnancy secondary to clinical parameters such as 
polyhydramnios or increased fetal abdominal 
circumference.  
The data collected included the method of 
diagnosis, gestational age at diagnosis, variations in 
HbA1c levels throughout pregnancy, management, 
gestational age and weight at delivery, any peri-
natal maternal or fetal complications and long term 
follow up of the mother. Macrosomia was classified 
as birth weight above 4.5kg.  Infants with weight 
above the 90th centile for gestational age were 
classified as large for gestational age. This was 
performed by ultrasound fetal measurements plotted 
on a growth chart. Data was collected on a 
proforma created using Microsoft Access. 
Nonparametric assessments were used. 
Assessments between categorical variables were 
analysed using χ2 test and Fisher’s exact test. 
Associations between independent samples were 
analysed using the Mann-Whitney U or Kruskal-
Wallis as appropriate. Correlation analyses were 
carried out using Spearman correlation. Statistical 
assessments were carried out using IBM SPSS® 
Statistics for Windows, Version 22.0, (IBM Corp. 
Armonk, NY, USA). A two-sided P < 0.05 was 
considered statistically significant.  
 
Results 
From a total of 79 pregnancies, 55 patients 
were diagnosed with GDM (69.6%), 13 patients had 
pre-existing type 1 DM (16.5%) and 11 patients had 
type 2DM (13.9%). The vast majority of GDM 
patients (50.9%) were started on oral 
hypoglycaemic agents specifically Metformin, 
while 32.7% required insulin mostly human insulin 
(Actrapid®) pre-prandially.  About 63.6% of Type 2 
DM patients were on insulin mostly combination 
regimes involving intermediate and short acting 
human insulins (Insulatard® and Actrapid®), 36.4% 
on both insulin and oral hypoglycaemic agents and 
18.2% on oral hypoglycaemic agents only 
(Metformin). All our Type 1 patients were on 
insulin, the majority of which were on insulin 
analogues (insulin glargine and insulin aspart). The 
median gestational age at which a GDM diagnosis 
was made was 29 weeks (IQR: 28-32).     
The mean fasting blood glucose in the GDM 
cohort was 6.31mmol/l (SD+/- 1.79), the mean 
blood glucose during the first hour of OGTT was 
12.06 mmol/l (SD+/- 2.77) and the mean second 
hour blood glucose was 10.73 mmol/l (SD+/- 2.95).  
The shortest mean gestational age of 35.5 
weeks was in the Type 2 DM cohort compared to 
37.1 and 37.9 weeks in the Type 1DM and GDM 
groups respectively (P=0.010). Type 1 DM mothers 
had generally a younger age (Mean +/- SD: 27.0 +/-
4.3 years) compared to GDM mothers (Mean +/- 
SD: 31.5 +/-6.8 years) and Type 2 DM mothers 
(Mean +/- SD: 32.4 +/-4.4 years) (P=0.031). 
The mean gestational weight in the GDM 
group was 3.5kg (+/-0.7 Kg) and the mean neonatal 
weight in the type 1and type 2 cohort was 3.2kg 
(P=0.041).  In 20.3% of patients, an antenatal scan 
showed a large for gestational age fetus, 23.6% of 
which were GDM pregnancies.  
The median HbA1c in the pre-conception 
period was 7.8 (IQR: 7.25-9.35 %) and 7.6 (IQR: 
6.65-8.18 %) in the Type 1 and Type 2 group 
respectively. In the Type 1DM cohort this went 
down to 7.4 in the first trimester and 7.2 and 7.1 in 
the second and third trimesters respectively.  In the 
Type 2DM group, the HbA1c declined gradually 
from 7 to 6.8 and 6.3 in the first, second and third 
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trimesters respectively.   
A statistically significant negative correlation 
(P=<0.001) was found between gestational age and 
HbA1c levels.  
During the intra-partum period 30% of GDM 
and 25.5% of Type 2 DM patients required an 
insulin infusion pump. However, as expected, up to 
84.6% of Type 1DM patients required an insulin 
infusion pump.  No metabolic complications were 
reported during the intra-partum period.  Apart from 
macrosomia, respiratory distress was common in 
babies of diabetic women, with a number of infants 
requiring neonatal intensive care admission for 
glucose monitoring. Two infants suffered a 
hypoglycaemia induced seizure at birth. Other 
neonatal complications reported include two intra-
uterine deaths in the GDM group and a number of 
organ anomalies in 3 fetuses in the Type 1 and 2 
group.  
Six weeks post-partum, 52% of GDM patients 
attended for an OGTT, 21.8% of which had Type 
2DM and 5.5% impaired glucose tolerance.  
 
Discussion 
Malta, an island in the Mediterranean Sea, has 
one of the highest rates of diabetes in Europe.5 The 
estimated prevalence of diabetes in adults was 
13.9% in 2015, according to the International 
Federation of Diabetes Atlas.  Moreover, the 
prevalence of gestational diabetes is on the rise. A 
study conducted by Aganovic et al, in 1983 has 
shown that the prevalence of gestational diabetes 
was 11.5%, compared to a prevalence of 16.5% in 
2010, according to IADPSG criteria.6-7 
Diabetes in pregnancy has well been 
recognized as the commonest medical condition 
complicating a pregnancy.   The effects of diabetes 
mellitus on the mother and her fetus can be 
described as diverse, complex and occasionally 
resulting in permanent end-organ damage. Albeit, in 
the vast majority of cases, complications can be 
avoided and prevented if the mother is followed-up 
closely and managed within a multi-disciplinary 
team.  Maternal obstetric complications include a 
higher risk of pre-eclampsia, pregnancy-induced 
hypertension, higher risk of operative vaginal 
delivery and caesarean section wound infection.7 
The well-known medical complications associated 
with diabetes and micro-vascular disease tend to get 
worse during pregnancy. Diabetic nephropathy has 
a worse prognosis during pregnancy when 
compared to equivalent stages of chronic kidney 
disease outside pregnancy.8  Pregnant Type 1 and 2 
DM patients, should be screened for diabetic 
nephropathy throughout pregnancy, with albumin-
creatinine ratio being a more accurate test.9 Around 
30 to 40% of diabetic patients suffer from chronic 
hypertension, however, during pregnancy 60 to 
70% of diabetic patients develop hypertension thus 
exacerbating any pre-existing nephropathy. 10,8 The 
changes associated with diabetic retinopathy 
progress in around 50-70% of cases.11 Screening 
should be done in the pre-conception period and in 
every trimester of pregnancy coupled with good 
blood pressure and glycaemic control.12 On a 
positive note, despite the programmed routine 
screening in our cohort of type 1 and 2 patients, no 
cases of progressive nephropathy or retinopathy 
complications were reported. Fetal complications 
include, an increased risk of first trimester 
miscarriage, congenital anomalies, macrosomia, 
stillbirth, shoulder dystocia, neo-natal 
hypoglycaemia and respiratory distress 
syndrome.13-14 
The IADPSG criteria were used for a 
diagnosis of gestational diabetes, in line with recent 
recommendations from the HAPO study.15 
Gestational diabetes can be defined as ‘any degree 
of glucose intolerance with onset or first recognition 
during pregnancy’.16-17  Our results show that the 
mean gestational age at delivery was highest in the 
GDM cohort compared to the Type 1 and Type 2 
group. One can possibly explain these results by the 
fact that obstetric patients with pre-gestational 
diabetes are considered to be high risk patients and 
hence the obstetricians will have a lower threshold 
to deliver the fetus prior to the estimated date of 
delivery. Moreover, the lowest gestational age was 
recorded in the Type 2 DM group of patients. We 
also report that patients with Type 2 DM tend to be 
older and with a higher BMI, these results are in 
agreement with other authors.18 
A strong positive correlation exists between 
percentage fetal body fat, fetal insulin levels and 
maternal glycaemia.15 On average, patients with 
GDM had a fetus of a higher gestational weight, 
while mean gestational weight in Type1 and 2 DM 
patients was similar. This could possibly be 
explained by a relatively later diagnosis, monitoring 
and initiation of treatment in the GDM cohort as 
compared to patients with pre-existing diabetes 
mellitus.  
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The HbA1c during the pre-conception period 
in the pre-diabetic patients was sub-optimal in both 
groups. The median HbA1c level in both groups 
improved during the first trimester possibly due to 
the decreased insulin requirements in the first 
trimester.   Nielsen et al have reported a decrease in 
HbA1c level, from 6.3% pre-pregnancy, to 5.6% in 
the third trimester in normal pregnant patients.19 
Moreover, the life span of erythrocytes during 
pregnancy shortens secondary to increased 
erythropoietin secretion.20 Therefore, irrespective of 
glycaemic control, HbA1c will drop during the first 
and third trimester, and lowering the threshold by 
0.4% in diabetic pregnancies will translate into 
better glycaemic monitoring during pregnancy.21 
The mean HbA1c levels remained highest in the 
Type 1DM group, throughout pregnancy. Adequate 
glycaemic control in Type 1DM during pregnancy 
is challenging mainly due to the risk of 
hypogylacemia coupled by peaks and troughs in 
insulin requirements which are not necessarily met 
by the insulin dosage regimen. 
Women with GDM have a higher risk of 
developing Type 2DM, despite the fact that in most 
cases euglycaemia is achieved immediately after 
delivery.21 All the GDM patients in our cohort were 
invited for a repeat OGTT 6 weeks after delivery. A 
low turnout of 52% was reported and 21.8% were 
diagnosed with Type 2DM. In a systemic review of 
20 studies, patients with gestational diabetes have a 
7-fold increased risk of developing Type 2DM
when compared to patients with a euglyacemic
pregnancy.22
Our study has shown a significant correlation 
between the different types of diabetes and 
pregnancy outcomes, emphasizing a known fact that 
pre-existing diabetes mellitus both Type 1 and 2, 
greatly determines obstetric outcomes. Our study 
has also confirmed the idea that women are at a 
higher risk of developing diabetes mellitus after a 
pregnancy affected by gestational diabetes.  This 
underpins the importance of prevention of diabetes, 
and the emphasis on follow up once the condition 
has been diagnosed.  
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